26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Cellular Biochemistry

• Publication date

  2001-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/jcb.1150PMID 11400168
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sodium salicylate inhibits proliferation and induces Gl cell cycle arrest in human pancreatic cancer cell lines

  2007cited by this paper
• Statistical Principles in Experimental Design

  2003cited by this paper
• Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas.

  2000cited by this paper
• Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation.

  2000influential reference
• Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer

  2000cited by this paper
• NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events.

  2000cited by this paper
• Cancer statistics, 2000

  2000cited by this paper
• A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296)

  2000cited by this paper
• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  1999cited by this paper
• The proteasome inhibitor PS-341 in cancer therapy.

  1999cited by this paper
• Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines.

  1999cited by this paper
• Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells.

  1999cited by this paper
• Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.

  1999cited by this paper
• Immunotherapy of Cancer

  1999cited by this paper
• Loss of p27Kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma.

  1999cited by this paper
• Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB

  1999influential reference
• Experimental drugs and drug combinations in pancreatic cancer.

  1999cited by this paper
• Apoptosis and the proteasome.

  1999cited by this paper
• Proteasome inhibitors: valuable new tools for cell biologists.

  1998cited by this paper
• The molecular and cellular biology of pancreatic cancer.

  1998cited by this paper
• NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.

  1998cited by this paper
• Degradation of tyrosine aminotransferase (TAT) via the ubiquitin–proteasome pathway

  1997cited by this paper
• p53-dependent Induction of Apoptosis by Proteasome Inhibitors*

  1997cited by this paper
• CHAPTER 28. NOVEL INHIBITORS OF THE PROTEASOME AND THEIR THERAPEUTIC USE IN INFLAMMATION

  1996cited by this paper
• How Proteolysis Drives the Cell Cycle

  1996cited by this paper
• TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB

  1996cited by this paper
• Cancer Cell Cycles

  1996cited by this paper
• Reduced survival in patients with ductal pancreatic adenocarcinoma associated with CDKN2 mutation.

  1996cited by this paper
• An essential role for NF-kappaB in preventing TNF-alpha-induced cell death.

  1996cited by this paper
• Effects on NF-κB1/p105 processing of the interaction between the HTLV-1 transactivator Tax and the proteasome

  1996cited by this paper
• Suppression of TNF-alpha-induced apoptosis by NF-kappaB.

  1996cited by this paper
• Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis.

  1996cited by this paper
• Suppression of TNF-α-Induced Apoptosis by NF-κB

  1996cited by this paper
• An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death

  1996cited by this paper
• Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B.

  1996cited by this paper
• Proteasomes play an essential role in thymocyte apoptosis.

  1996cited by this paper
• Involvement of the proteasome in the programmed cell death of NGF‐deprived sympathetic neurons.

  1996cited by this paper
• TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB.

  1996cited by this paper
• Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells.

  1995cited by this paper
• Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

  1995influential reference
• Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules.

  1994cited by this paper
• Apoptosis in cancer therapy: crossing the threshold.

  1994cited by this paper
• Cyclin is degraded by the ubiquitin pathway

  1991influential reference
• The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.

  1990influential reference
• A sensitive and rapid gel retention assay for nuclear factor I and other DNA-binding proteins in crude nuclear extracts.

  1986cited by this paper
• Multiple nuclear factors interact with the immunoglobulin enhancer sequences.

  1986cited by this paper
• Statistical Principles in Experimental Design

  1963cited by this paper

• Ki67 and TNFRII as Potential Clinical Markers for Effective Clinical Staging of Advanced Prostate Cancer

  2025cites this paper
• Bortezomib exerts its anti-cancer activity through the regulation of Skp2/p53 axis in non-melanoma skin cancer cells and C. elegans

  2024cites this paper
• Understanding the Biological Basis of Polygenic Risk Scores and Disparities in Prostate Cancer: A Comprehensive Genomic Analysis

  2024cites this paper
• Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro.

  2024cites this paper
• Anti-tumor effect of proteasome inhibitor on canine urothelial carcinoma

  2024cites this paper
• Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer

  2024cites this paper
• Modulation of the ubiquitin‐proteasome system by phytochemicals: Therapeutic implications in malignancies with an emphasis on brain tumors

  2023cites this paper
• New trends in synthetic drugs and natural products targeting 20S proteasomes in cancers.

  2023cites this paper
• Prognostic and Immune Infiltration Value of Proteasome Assembly Chaperone (PSMG) Family Genes in Lung Adenocarcinoma

  2023cites this paper
• The role of proteasomes in tumorigenesis

  2023cites this paper
• Surveying the landscape of emerging and understudied cell death mechanisms.

  2023cites this paper
• Expanding the ubiquitin code in pancreatic cancer.

  2023cites this paper
• Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review

  2022cites this paper
• FBXL16 Promotes Endometrial Progesterone Resistance via PP2AB55α/Cyclin D1 Axis in Ishikawa

  2022cites this paper
• Synthesis of Novel Derivatives of 1-Metoxy-3-methylcarbazole – Murrayafoline A Alkaloid

  2021cites this paper
• Advances in Proteasome Enhancement by Small Molecules

  2021cites this paper
• Treating MCF7 breast cancer cell with proteasome inhibitor Bortezomib restores apoptotic factors and sensitizes cell to Docetaxel

  2021cites this paper
• Macromolecular Protein Complexes III: Structure and Function

  2021cites this paper
• Identification of PSMD7 as a prognostic factor correlated with immune infiltration in head and neck squamous cell carcinoma

  2021cites this paper
• Discovery of selective fragment-sized immunoproteasome inhibitors.

  2021cites this paper
• Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells

  2021cites this paper
• Structure, Dynamics and Function of the 26S Proteasome.

  2021cites this paper
• Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads

  2021cites this paper
• Identification of PSMD7 as a prognostic factor correlated with immune infiltration in head and neck squamous cell carcinoma

  2021cites this paper
• Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia

  2021cites this paper
• The Proteasome Inhibitor Bortezomib Induces Tongue, Pharynx and Salivary Gland Cancer Cells Death in Vitro and Delays Tumor Growth of Salivary Gland Cancer Cells Transplanted in Mice

  2021cites this paper
• Proteasome Inhibitor Drugs.

  2020cites this paper
• Deubiquitinase PSMD7 regulates cell fate and is associated with disease progression in breast cancer.

  2020cites this paper
• Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib

  2020cites this paper
• Effects of tris (2-chloroethyl) phosphate (TCEP) on growth, reproduction and gene transcription in the protozoan Tetrahymena thermophila.

  2020cites this paper
• Synthesis and evaluation of tiaprofenic acid-derived UCHL5 deubiquitinase inhibitors.

  2020cites this paper
• A Practical Review of Proteasome Pharmacology

  2019cites this paper
• Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research

  2019cites this paper
• Apoptosis: Signaling pathways in pancreatic cancer pathogenesis

  2018cites this paper
• The effects of bortezomib on the ovariectomy applied rat uterus: A histopathological, stereological, and immunohistochemical study

  2018cites this paper
• Investigating Intestinal Permeability of Bortezomib Using a Validated HPLC-UV Method

  2018cites this paper
• Screening Combinatorial Peptide Libraries in Protease Inhibitor Drug Discovery

  2018cites this paper
• A new gold(I) complex-Au(PPh3)PT is a deubiquitinase inhibitor and inhibits tumor growth

  2018cites this paper
• Potential protein biomarkers of QX disease resistance in selectively bred Sydney Rock Oysters

  2018cites this paper
• Bortezomib-loaded solid lipid nanoparticles: preparation, characterization, and intestinal permeability investigation

  2018cites this paper
• Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases

  2017cites this paper
• Understanding the role of Bcl-3 in breast cancer metastasis

  2017cites this paper
• Immunoregulatory therapies for inflammatory diseases

  2016cites this paper
• Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.

  2015cites this paper
• Nuclear factor-kappaB in inflammatory bowel disease and colorectal cancer

  2015cites this paper
• Effect of NF-κB inhibition on chemoresistance in biliary–pancreatic cancer

  2015cites this paper
• Bortezomib enhances the radiosensitivity of hypoxic cervical cancer cells by inhibiting HIF-1α expression.

  2015cites this paper
• Investigating proteasome inhibitors as potential adjunct therapies for experimental cerebral malaria

  2015cites this paper
• Clusterin silencing sensitizes pancreatic cancer MIA-PaCa-2 cells to gmcitabine via regulation of NF-kB/Bcl-2 signaling.

  2015cites this paper
• Differential impact of bortezomib on HL-60 and K562 cells.

  2015cites this paper
• [Proteasome inhibitors in cancer therapy].

  2015cites this paper
• MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer

  2015cites this paper
• Review Article Nuclear factor-kappaB in inflammatory bowel disease and colorectal cancer

  2014cites this paper
• Identification and characterization of a proteasome deubiquitinase inhibitor

  2014cites this paper
• Targeting Mantle Cell Lymphoma with a Strategy of Combined Proteasome and Histone Deacetylase Inhibition

  2014cites this paper
• Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NF‑κB.

  2014influential citation
• IDENTIFICATION OF MOLECULAR MECHANISMS RESPONSIBLE FOR DEGRADATION OF THE TUMOR SUPPRESSOR PROTEIN NUMB IN CANCER.

  2014cites this paper
• Neurochemical characterization of primary sensory neurons in a rat model of bortezomic-induced peripheral neuropathy

  2014cites this paper
• Overexpression of Nuclear Apoptosis-Inducing Factor 1 Altered the Proteomic Profile of Human Gastric Cancer Cell MKN45 and Induced Cell Cycle Arrest at G1/S Phase

  2014cites this paper
• Proteasome Inhibitors and Lessons Learned from Their Mechanisms of Action and Resistance in Human Cancer

  2014cites this paper
• Trial Watch: Proteasomal inhibitors for anticancer therapy

  2014cites this paper
• B and H-NMR Evaluation of Chemical Interactions Between Two Polyphenols; Epigallocatechingallate and Quercetin with Bortezomib

  2014cites this paper
• Molecular Studies On The Anti-Tumor Effects Of Metal-Based Complexes: Involvement Of The Ubiquitin-Proteasome And Apoptotic Pathways

  2014cites this paper
• Network‐based identification of key proteins involved in apoptosis and cell cycle regulation

  2014cites this paper
• Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach

  2014cites this paper
• Inhibition of ubiquitin-proteasome pathway: A possible treatment of hepatocellular carcinoma

  2013cites this paper
• Pancreatic Cancer Experimental and Clinical Studies

  2013cites this paper
• Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production

  2013cites this paper
• Targeting apoptosis pathways in pancreatic cancer.

  2013cites this paper
• Use of in vitro primary culture models to investigate the activity of standard and novel therapies in haematological malignancies

  2013cites this paper
• SAR analysis and bioactive potentials of freshwater and terrestrial cyanobacterial compounds: a review

  2013cites this paper
• Molecularly Targeted Therapies in Metastatic Pancreatic Cancer: A Systematic Review

  2013cites this paper
• Proteasome inhibition as a new strategy in cancer therapy and chemoprevention

  2013cites this paper
• Proteasomal regulation of caspase-8 in cancer cell apoptosis

  2013cites this paper
• [Proteasome inhibition as a new strategy in cancer therapy and chemoprevention].

  2013cites this paper
• Intracellular mechanisms of apoptosis induced by aminoglycoside antibiotics

  2013cites this paper
• Targeting the NF-κB pathway in cancer therapy.

  2013cites this paper
• Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer.

  2013cites this paper
• Free radicals and antioxidants: how to reestablish redox homeostasis in chronic diseases?

  2013cites this paper
• Proteomic analysis of HSP90 inhibitor effects on human leukemia cells

  2013cites this paper
• Proteasome and cancer.

  2012cites this paper
• Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma

  2012cites this paper
• PROTEASOME REGULATION OF CASPASE-8: SIGNIFICANCE IN CANCER

  2012cites this paper
• A phase I study of bortezomib and temozolomide in patients with advanced solid tumors

  2012cites this paper
• Protein Oxidation in Some Age‐Related Diseases

  2012cites this paper
• Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.

  2012cites this paper
• The ‘N-factors' in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer

  2012cites this paper
• Targeted agents in second-line bladder cancer therapy

  2012cites this paper
• Noxa/Mcl-1 balance influences the effect of the proteasome inhibitor MG-132 in combination with anticancer agents in pancreatic cancer cell lines

  2012cites this paper
• Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

  2011cites this paper
• Basic concepts of inflammation and its role in carcinogenesis.

  2011cites this paper
• Altered Responses to Endoplasmic Reticulum Stress in Pancreatic Cancer

  2011cites this paper
• Bortezomib in Waldenstrom’s Macroglobulinemia

  2011cites this paper
• Long-term macrolide antibiotics in asthma therapy

  2011cites this paper
• Proteolysis-inducing factor core peptide mediates dermcidin-induced proliferation of hepatic cells through multiple signalling networks.

  2011cites this paper
• Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer

  2011cites this paper
• Advances in the understanding of mechanisms and therapeutic use of bortezomib.

  2011cites this paper
• DNA Repair, Cancer and Cancer Therapy

  2011cites this paper
• The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer

  2011cites this paper
• Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.

  2011cites this paper